SUPERNUS PHARMACEUTICALS, INC. Operating Lease Cost
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Operating Lease Cost of $15.73 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-02
- SUPERNUS PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2020-03-31 was $2.12M, a 41.88% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2019-12-31 was $1.89M.
- SUPERNUS PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2019-09-30 was $1.98M.
- SUPERNUS PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2019-06-30 was $1.50M.
- SUPERNUS PHARMACEUTICALS, INC. operating lease, cost for fiscal 2025 was $15.73M, a 9.08% increase from fiscal 2024.
- SUPERNUS PHARMACEUTICALS, INC. operating lease, cost for fiscal 2024 was $14.42M, a 1.15% increase from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. operating lease, cost for fiscal 2023 was $14.26M, a 10.97% increase from fiscal 2022.
- SUPERNUS PHARMACEUTICALS, INC. operating lease, cost for fiscal 2022 was $12.85M, a 7.17% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $15.73M 10-K · filed 2026-03-02 | |||
| 2024-12-31 | $14.42M 10-K · filed 2026-03-02 | |||
| 2023-12-31 | $14.26M 10-K · filed 2026-03-02 | |||
| 2022-12-31 | $12.85M 10-K · filed 2025-02-25 | |||
| 2021-12-31 | $11.99M 10-K · filed 2023-03-09 | |||
| 2020-12-31 | $7.48M 10-K · filed 2022-04-13 | |||
| 2020-03-31 | $2.12M 10-Q · filed 2020-05-15 | $4.02M derived: sum of 2 quarters · filed 2021-03-08 | $6.00M derived: sum of 3 quarters · filed 2021-03-08 | $7.50M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $3.88M derived: sum of 2 quarters · filed 2021-03-08 | $5.38M derived: sum of 3 quarters · filed 2021-03-08 | $6.88M 10-K · filed 2021-03-08 |
| 2019-09-30 | $1.98M 10-Q · filed 2019-11-08 | $3.49M derived: sum of 2 quarters · filed 2019-11-08 | $4.98M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $1.50M 10-Q · filed 2019-08-09 | $3.00M 10-Q · filed 2019-08-09 | ||
| 2019-03-31 | $1.50M 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |